Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25.
The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by providing clinicians with results that are both accurate and rapidly obtained. Herein, we review molecularly based infectious disease diagnostic tests that are Food and Drug Administration approved or cleared and commercially available in the United States as of December 31, 2010. We describe specific assays and their performance, as stated in the Food and Drug Administration's Summary of Safety and Effectiveness Data or the Office of In Vitro Diagnostic Device Evaluation and Safety's decision summaries, product inserts, or peer-reviewed literature. We summarize indications for testing, limitations, and challenges related to implementation in a clinical laboratory setting for a wide variety of common pathogens. The information presented in this review will be particularly useful for laboratories that plan to implement or expand their molecular offerings in the near term.
分子检测的高灵敏度和特异性极大地提高了传染病诊断领域的水平,为临床医生提供了准确、快速的检测结果。本文回顾了截至 2010 年 12 月 31 日,美国食品药品监督管理局(FDA)批准或通过的、商业化的基于分子的传染病诊断检测方法。我们描述了特定的检测方法及其性能,依据来自 FDA 的安全性和有效性数据概要,或体外诊断设备评估和安全办公室的决策总结、产品说明书,或同行评议文献。我们总结了针对各种常见病原体的检测指征、局限性和在临床实验室实施的相关挑战。本文所提供的信息对那些计划在近期内实施或扩展其分子检测的实验室尤其有用。